Related references
Note: Only part of the references are listed.The Jekyll and Hyde of Cellular Senescence in Cancer
Dilara Demirci et al.
CELLS (2021)
Therapy-Induced Senescence: An Old Friend Becomes the Enemy
Tareq Saleh et al.
CANCERS (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018)
F. Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Senescent Cells in Cancer Therapy: Friends or Foes?
Boshi Wang et al.
TRENDS IN CANCER (2020)
Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer
Thu-Huyen Pham et al.
CELL COMMUNICATION AND SIGNALING (2019)
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
Eduardo Tormo et al.
SCIENTIFIC REPORTS (2019)
Endoreplication: The Good, the Bad, and the Ugly
Zhiqiang Shu et al.
TRENDS IN CELL BIOLOGY (2018)
The Novel Small Molecule STK899704 Promotes Senescence of the Human A549 NSCLC Cells by Inducing DNA Damage Responses and Cell Cycle Arrest
Chan-Woo Park et al.
FRONTIERS IN PHARMACOLOGY (2018)
Chromosomal instability-induced senescence potentiates cell non-autonomous tumourigenic effects
Qianqian He et al.
ONCOGENESIS (2018)
Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse
Marco Demaria et al.
CANCER DISCOVERY (2017)
Nucleolar expansion and elevated protein translation in premature aging
Abigail Buchwalter et al.
NATURE COMMUNICATIONS (2017)
Rapid Profiling Cell Cycle by Flow Cytometry Using Concurrent Staining of DNA and Mitotic Markers
Yuqing Shen et al.
BIO-PROTOCOL (2017)
Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line
Seyma Aydinlik et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2017)
Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines
Nesstor Pilco-Ferreto et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer
Yesol Bak et al.
ONCOTARGET (2016)
Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues
EA Georgakopoulou et al.
Aging-US (2016)
Cellular senescence in aging and age-related disease: from mechanisms to therapy
Bennett G. Childs et al.
NATURE MEDICINE (2015)
IL-32θ gene expression in acute myeloid leukemia suppresses TNF-α production
Man Sub Kim et al.
ONCOTARGET (2015)
Polyploidy Formation in Doxorubicin-Treated Cancer Cells Can Favor Escape from Senescence
Grazyna Mosieniak et al.
NEOPLASIA (2015)
Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway
Ting Chen et al.
CANCER BIOLOGY & THERAPY (2015)
Interaction network mapping among IL-32 isoforms
Jeong-Woo Kang et al.
BIOCHIMIE (2014)
Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim
Hye-Kyung Park et al.
BMC CANCER (2014)
IL-32θ negatively regulates IL-1β production through its interaction with PKCδ and the inhibition of PU.1 phosphorylation
Man Sub Kim et al.
FEBS LETTERS (2014)
Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway
Jeong Su Park et al.
CELLULAR ONCOLOGY (2013)
p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer
James G. Jackson et al.
CANCER CELL (2012)
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin et al.
NATURE METHODS (2012)
Pro-senescence therapy for cancer treatment
Caterina Nardella et al.
NATURE REVIEWS CANCER (2011)
The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
Jean -Philippe Coppe et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
Therapy-Induced Senescence in Cancer
Jonathan A. Ewald et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells
S. Teissier et al.
ONCOGENE (2010)
Cyclin D1 Degradation Is Sufficient to Induce G1 Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer Cells
Chioniso Patience Masamha et al.
CANCER RESEARCH (2009)
Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer
Ralph A. Neumueller et al.
GENES & DEVELOPMENT (2009)
Induction of senescence with doxorubicin leads to increased genomic instability of HCT1 16 cells
Malgorzata A. Sliwinska et al.
MECHANISMS OF AGEING AND DEVELOPMENT (2009)
Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy
Pierre-Emmanuel Puig et al.
CELL BIOLOGY INTERNATIONAL (2008)
Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells
Ortal Bar-On et al.
ANTI-CANCER DRUGS (2007)
Quantification of mRNA using real-time RT-PCR
Tania Nolan et al.
NATURE PROTOCOLS (2006)
A dual role of Cyclin E in cell proliferation and apotosis may provide a target for cancer therapy
S Mazumder et al.
CURRENT CANCER DRUG TARGETS (2004)
Abnormal nuclear shape in solid tumors reflects mitotic instability
D Gisselsson et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
